[Skip to Content]
[Skip to Content Landing]
November 12, 2008

Aspirin for Primary Prevention of Cardiovascular Events in Diabetes: Still an Open Question

Author Affiliations

Author Affiliations: Department of Clinical Pharmacology and Epidemiology, Consorzio Mario Negri Sud, S. Maria Imbaro, Italy.

JAMA. 2008;300(18):2180-2181. doi:10.1001/jama.2008.625

The use of aspirin for primary prevention of cardiovascular events in individuals with diabetes is widely recommended by existing guidelines, but the evidence supporting its efficacy is surprisingly scarce.1 Recommendations seem based mainly on extrapolations from data from other high-risk groups, rather than on solid data derived from studies conducted specifically in patients with diabetes. Indeed, an increasing amount of evidence suggests that the efficacy of antiplatelet therapy in patients with diabetes may be lower than in individuals without diabetes.2